Featured News Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells April 12, 2022 Read More Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022 March 28, 2022 Read More Press Releases Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022) May 10, 2022 READ MORE Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells April 12, 2022 READ MORE Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022 March 28, 2022 READ MORE Shoreline Biosciences Appoints Robert Hollingsworth, Ph.D., As Chief Scientific Officer March 15, 2022 READ MORE Shoreline Biosciences to Present Multiple Posters on iPSC-Derived NK Cell Platform at AACR Annual Meeting 2022 March 9, 2022 READ MORE Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires February 15, 2022 READ MORE LOAD MORE Media BioWorld Insider Podcast: One-on-one with Medical Innovators February 7, 2022 READ MORE Harnessing the body’s natural killers to target cancer December 5, 2021 READ MORE Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing November 8, 2021 READ MORE California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award November 4, 2021 READ MORE Developing Allogeneic Induced Pluripotent Stem Cell Based Therapies to Kill Cancer Cells with Kleanthis Xanthopoulos Shoreline Biosciences November 4, 2021 READ MORE Shoreline Biosciences – (iPSC)-Derived Allogeneic Natural Killer (NK) and Macrophage Products November 3, 2021 READ MORE LOAD MORE
Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022) May 10, 2022 READ MORE
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells April 12, 2022 READ MORE
Shoreline Biosciences Announces Oral Presentation on iPSC-Derived NK Cell (iNK) Platform at Innate Killer Summit Meeting 2022 March 28, 2022 READ MORE
Shoreline Biosciences Appoints Robert Hollingsworth, Ph.D., As Chief Scientific Officer March 15, 2022 READ MORE
Shoreline Biosciences to Present Multiple Posters on iPSC-Derived NK Cell Platform at AACR Annual Meeting 2022 March 9, 2022 READ MORE
Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires February 15, 2022 READ MORE
Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing November 8, 2021 READ MORE
California Life Sciences awarded Kite Pharma, a Gilead company, and Shoreline Biosciences the 2021 Strategic Partnership of the Year Award November 4, 2021 READ MORE
Developing Allogeneic Induced Pluripotent Stem Cell Based Therapies to Kill Cancer Cells with Kleanthis Xanthopoulos Shoreline Biosciences November 4, 2021 READ MORE
Shoreline Biosciences – (iPSC)-Derived Allogeneic Natural Killer (NK) and Macrophage Products November 3, 2021 READ MORE
